JOHN HOLLOWAY: Open Payments
NPI 1154152288 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$399 in 25 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $201 · 2025 $399
Food & beverage: $379Education: $20
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 12 | $160 |
| Mallinckrodt Hospital Products Inc. | 4 | $80 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $42 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| OPKO Pharmaceuticals, LLC | 1 | $20 |
| Calliditas Therapeutics US Inc. | 1 | $15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $14 |
Products named: Fabhalta, ACTHAR, Kerendia, Vanrafia, FARXIGA, VOYXACT, RAYALDEE, TARPEYO.
Industry payments across DE — which companies pay providers there.
